Verition Fund Management’s BioNTech BNTX Stock Holding History

Verition Fund Management’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$837K	Hold	9,000	–	–	﹤0.01%	1484
2026 Q1	$800K	Sell	9,000 -4,600	-34%	-$473K	0.01%	1403
2025 Q4	$1.29M	Sell	13,600 -15,000	-52%	-$1.51M	0.01%	1956
2025 Q3	$2.82M	Buy	28,600 +20,300	+245%	+$2.17M	0.01%	1684
2025 Q2	$884K	Buy	+8,300	New	+$838K	﹤0.01%	2565

Other funds holding BNTX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Flossbach Von Storch Cologne, Germany $22.1B AUM 6.81% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

GSK plc London $602M AUM

Verition Fund Management's BNTX Position: Q2 2026 in Review

Verition Fund Management reduced its BioNTech (BNTX) stake by 9.1% in Q2 2026, selling an estimated $44K and leaving 4,658 shares worth $433K. The position accounts for ﹤0.01% of the portfolio, ranked #1675.

Verition Fund Management first reported a position in BNTX in Q4 2020 and has held it in 7 quarters since. The position peaked at $1.93M in Q4 2024. 282 funds tracked by Wall St. Rank hold BNTX as of Q2 2026.

Verition Fund Management held 4,658 shares of BioNTech worth $433K as of Q2 2026.
Verition Fund Management sold 468 BioNTech shares in Q2 2026, an estimated $44K.
BioNTech made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1675 holding.
Verition Fund Management first reported a position in BioNTech in Q4 2020 and has held it in 7 quarters since.
Verition Fund Management's BioNTech position peaked at $1.93M in Q4 2024.
282 funds tracked by Wall St. Rank held BioNTech as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.